Provention Bio Inc (PRVB) received a Buy rating and a $7.50 price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares closed yesterday at $2.22, close to its 52-week low of $1.52.
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -15.3% and a 24.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Provention Bio Inc is a Moderate Buy with an average price target of $7.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8 and a one-year low of $1.52. Currently, Provention Bio Inc has an average volume of 52.42K.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRVB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the developement of biopharmaceutical products. It focuses its product line on type 1 diabetes, Crohn’s disease, ulcerative colitis, and emerging viral infections.
